Skip to main content

Advertisement

Table 1 Savings (vs. null scenario) as a result of implementing universal screening for GBS (NIS at 2010 price levels)

From: Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

TREATMENT COSTS Marginal Risk-factor Universal Savings
  Unit costs Screening Screening  
Hospitalization     
Fatal and non-fatal anaphylaxis 4,301 3,686 20,890  
Fatality vs. non-GBS 1,997 2,347 968  
Sepsis vs. non GBS 11,441 419,988 173,336  
Meningitis & sepsis vs. non-GBS 14,710 59,998 24,762  
Post-Hospital Care vs. non-GBS 2,130 89,393 36,894  
   575,412 256,851 318,561
LTC     
Deafness 508,260 104,858 43,227  
Severe Neuro 2,640,519 1,604,008 662,002  
Moderate Neuro 1,281,790 828,425 341,906  
Mild Neuro 316,180 216,369 89,299  
   2,753,659 908,003 1,617,175
Total Health Service Costs   2,775,870 1,136,483 1,935,737
Lifetime productivity losses   1,382,007 570,378 811,828
Total Societal Costs   4,711,077 1,963,713 2,747,365